Updates in HCV Screening and Treatment Key Issues Impacting OB/GYN Practice

Nancy S. Reau, MD; Joanne L. Stone, MD, MSHCDL

Jointly provided by Postgraduate Institute for Medicine and Integritas Communications


This activity is supported by an independent educational grant from Gilead Sciences, Inc.


Nancy S. Reau, MD
The Richard B. Capps Chair of Hepatology
Professor, Department of Internal Medicine
Division of Digestive Diseases and Nutrition
Rush Medical College
Chief, Section of Hepatology
Associate Director of Organ Transplantation
Rush University Medical Center
Chicago, Illinois

Joanne L. Stone, MD, MSHCDL
Professor, Obstetrics, Gynecology, and Reproductive Science
Director, Division of Maternal-Fetal Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Target Audience

This activity is intended to educate obstetrics/gynecology (OB/GYN) physicians, physician assistants, nurse practitioners, and nurse midwives on appropriate hepatitis C virus (HCV) screening, testing, and referral practices for their patients.

Program Description

This educational activity is designed to better prepare OB/GYNs to identify patients who should be screened for HCV based on relevant professional society recommendations, appropriately link patients to care, and manage pregnancies of women who have HCV. Expert faculty will provide practical information on HCV screening, confirmatory testing, patient education, and counseling strategies for use within the real-world clinical context of OB/GYN practice. Although HCV affects women across diverse age groups and demographics, pregnancy raises additional considerations and risks for the HCV-infected mother and her unborn child, including mother-to-child-transmission of the virus, for which faculty will share recommendations and management insights.  

Educational Objectives

Upon completion of this activity, participants will be better able to:

  • Provide proactive HCV screening and confirmatory testing for OB/GYN patients per guidelines from the American Association for the Study of Liver Disease and the Society for Maternal-Fetal Medicine
  • Counsel patients on the implications of HCV infection, efficacy and safety of current direct-acting antiviral treatment regimens for chronic HCV infection, and behavioral risk reduction
  • Coordinate appropriate referrals and multidisciplinary care for HCV-infected women presenting in OB/GYN practices

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. 

CME Inquiries/Special Needs

For questions regarding the accreditation of this program, please contact PIM at

Disclosure of Conflicts of Interest

PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Nancy S. Reau, MD: Consulting Fees: AbbVie Inc., Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Merck & Co., Inc.; Contracted Research: GENFIT SA, Intercept Pharmaceuticals, Inc., Shire plc

Joanne L. Stone, MD, MSHCDL: Dr. Stone has no financial relationships to disclose

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Method of Participation and Request for Credit

There are no fees for participating and receiving CME/CE credit for this activity. During the period January 22, 2019 through January 22, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgement for completing this activity, please complete the post-test and evaluation. Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

expiration 01/29/2020